The EMJ Podcast: Insights For Healthcare Professionals

In this episode, Satish Raj and Gert van Dijk explore the diagnosis, clinical burden, and management of orthostatic hypotension. The discussion examines how low blood pressure affects daily functioning, the importance of accurate diagnosis, and current treatment approaches.  Key Discussion Themes Definitions and subtypes of orthostatic hypotension Differential diagnosis and the role of tilt-table testing  Impact on quality of life and daily functioning  Current treatment landscape and clinical guidelines  Unmet needs and future research priorities 

In this episode, Aaron Phillips discusses haemodynamic instability following spinal cord injury, with particular focus on autonomic dysreflexia. The conversation reviews the neuronal mechanisms underpinning autonomic dysfunction, the clinical burden of hypertensive and hypotensive complications, and current management strategies. The episode also explores emerging therapeutic approaches, including the development and evaluation of implantable systems designed to restore haemodynamic stability.  Key Discussion Themes  Definition and clinical features of haemodynamic instability  Autonomic dysreflexia: mechanisms and patient impact  Chronic hypertensive and hypotensive complications 

In the final episode of the series, David Goldstein examines orthostatic hypotension as a manifestation of autonomic failure in Parkinson's disease. The discussion explores the pathophysiology of cardiac noradrenergic deficiency, its identification and clinical implications, and current management approaches. The episode also considers the prognostic significance of orthostatic hypotension in Parkinson's disease and potential future directions in research and patient care.  Key Discussion Themes  Autonomic failure in Parkinson's disease  Cardiac noradrenergic deficiency: definition and identification  Clinical consequences, including falls and cognitive impairment  Mechanistic insights into sympathetic denervation  Current treatment approaches and guideline considerations  Future research priorities 

Debbie Palmer joins host Catherine Glass to explore how maternal diet shapes fetal immune development and influences allergy risk. This episode unpacks key nutrients, timing of dietary exposures, and findings from randomised trials that challenge conventional pregnancy nutrition advice.  Timestamps:  01:22 – Maternal diet  02:59 – Mid-pregnancy versus preconception  03:53 – Food groups  04:28 – Prebiotic supplements  05:30 – Pregnancy cravings 

In this rapid-fire episode, Debbie Palmer answers key questions on allergy prevention, from pregnancy nutrition myths and early allergen introduction to common misconceptions among clinicians and parents. A concise overview of cutting-edge thinking in just a few minutes. 

This episode has been funded by Sun Pharmaceutical Industries, Inc. Please see full Prescribing Information and the Patient Information for clascoterone cream 1%. Sebum plays a central role in acne pathogenesis. In this AMJ Rapid Review, Zoe Diana Draelos, MD, breaks down what new 52-week findings with clascoterone cream 1% may mean for everyday dermatology practice. In under 15 minutes, learn: How did the study objectively measure sebum, and what makes that approach clinically useful? What did the 52-week results reveal about changes over time, beyond what you see in the first few visits? How might sebum trends relate to standard acne assessments in longer-term follow-up? What practical expectations and counseling tips can help patients stay on track with treatment?  Speaker: Zoe Diana Draelos, MD Dermatology Consulting Services, PLLC, North Carolina, USA   IMPORTANT SAFETY INFORMATION Indication What is WINLEVI cream? WINLEVI (clascoterone) cream 1% is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 12 years of age and older. It is not known if WINLEVI cream is safe and effective in children under 12 years of age. Important Patient Information Before using WINLEVI cream, tell your healthcare provider about all of your medical conditions, particularly if you: have skin problems, including eczema, cuts or sunburn are pregnant or plan to become pregnant. It is not known if WINLEVI cream will harm your unborn baby are breastfeeding or plan to breastfeed. It is not known if WINLEVI cream passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with WINLEVI cream WINLEVI cream is for use on the skin only (topical). Do not use WINLEVI cream in or on your eyes, mouth, or vagina. Do not use WINLEVI cream for a condition for which it was not prescribed. Do not give WINLEVI cream to other people, even if they have the same symptoms you have. It may harm them. What are the possible side effects of WINLEVI cream? WINLEVI cream can cause serious side effects, including: local skin reactions. WINLEVI cream may cause local skin irritation including itching, burning, skin redness or peeling. symptoms of a disorder where the adrenal gland does not make enough of certain hormones (adrenal insufficiency) during treatment with WINLEVI. Your healthcare provider may stop your treatment with WINLEVI if you develop any adrenal problems. The most common side effects of WINLEVI cream include reddening, scaling or dryness, and itching of the skin being treated. These are not all of the possible side effects of WINLEVI cream. Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to Sun Pharmaceutical Industries, Inc. by calling 1-800-818-4555. Please see full Prescribing Information and the Patient Information.

In this first deep dive, Leslie Cho explores how lipidology and hormone therapy intersect in women's cardiovascular care. Drawing on major guideline work and trial data, she explains how clinicians should approach menopausal hormone therapy, complex lipid disorders, microvascular disease, and emerging therapies through a precision lens.  Timestamps:  01:10 – Menopausal hormone therapy  03:45 – Lipid-lowering therapy  05:55 – Microvascular disease  07:55 – Testosterone therapy 

In this rapid-fire episode, Leslie Cho answers essential questions on women's cardiovascular health, from overlooked risk factors and lipid values to myths about chest pain, microvascular disease, menopause, and the future of precision cardiology.

In the final deep dive, Matteo Bassetti discusses antimicrobial resistance beyond the bedside: translating evidence into policy, the importance of national surveillance, lessons from sepsis and COVID-19, and the future of antibiotic innovation and hospital preparedness. Timestamps: 01:24 – Translating evidence into policy 02:54 – National surveillance 04:15 – Sepsis and COVID-19 06:18 – Investment shortfalls 08:41 – Antibiotic crisis 10:19 – Looking ahead

In the second deep dive, Matteo Bassetti examines antibiotic stewardship where policy meets practice. He highlights gaps between guidelines and bedside realities, practical interventions for limited-resource settings, and balancing preservation of new antibiotics with effective treatment today. Timestamps: 01:27 – Guideline gaps 04:40 – Encouraging stewardship 06:23 – Realistic interventions 09:59 – Antibiotic shortages 11:16 – Preserving new drugs

In this episode of Hema Now, Ana Boban discusses her vision as the incoming EAHAD President for 2026–2028. From her early experiences in haemophilia care to her leadership in European clinical trials and guideline development, she reflects on the future of bleeding disorders in Europe, highlighting the importance of supporting young clinicians and researchers, advancing clinical practice, and driving innovation in haemophilia care and research.  Timestamps:   00:00 – Introduction   01:38 - Vision for EAHAD Presidency  03:50 - Building on Past Leadership  06:45 - Key Priorities: Practice, Research, Education  09:05 - EAHAD Congress Highlights  11:20 - European Haemophilia Landscape Today  14:17 - Advances Influencing Clinical Care  16:14 - Unmet Needs in Europe  17:45 - Supporting Young Clinicians, Researchers  20:00 - Long-Term Goals Beyond 2028  TBC- Three Wishes for Haemophilia

1.      In this first deep dive, Bassetti discusses the changing landscape of antimicrobial resistance in hospitals and ICUs, the challenges of multidrug-resistant Gram-negative bacteria, and the vulnerability of patients who are critically ill and immunocompromised. He explores how diagnosis, empiric therapy, and therapeutic monitoring influence outcomes and resistance. Timestamps: 01:09 – Antimicrobial resistance trends 04:06 – Tackling sepsis 06:39 – Gram-negative threat 08:15 – Vulnerable populations 10:00 – Diagnosis and empiric therapy 12:14 – Dosing and pharmacokinetics 14:32 – Antibiotic allergies

Matteo Bassetti joins the EMJ Podcast for a rapid-fire discussion on antimicrobial resistance in hospitals. From prescribing pitfalls to early versus precise antibiotic use, he shares insights on howantimicrobial resistance is impacting real-world clinical care.

Drawing on her landmark work in HIV and vaccine research, Glenda Gray shares powerful lessons for tackling AMR in this last deep dive episode. From prevention and behavioural science to protecting high-risk populations, she explains how strategies that transformed HIV outcomes can inform a more effective and equitable AMR response. Timestamps: 00:00 – Introduction 01:02 – Lessons from HIV 02:47 – Vaccine trials 03:50 – AMR interventions 05:17 – Behavioural science 06:31 – Key takeaways

In this second deep dive, Glenda Gray examines why the global antibiotic pipeline is failing and how access gaps are fuelling resistance. She discusses GARDP's mission-driven research and development model, the neglect of paediatric antibiotics, and how shortages of first-line treatments drive reliance on last-resort drugs, worsening the antimicrobial resistance crisis. Timestamps: 00:00 – Introduction 00:58 – Antibiotic development 03:05 – GARDP's model 04:15 – Paediatric antibiotics 04:58 – Antibiotic shortages 05:50 – Access gaps

In this episode of Onc Now, Michael Cecchini, Associate Professor of Medicine at Yale School of Medicine, New Haven, Connecticut, USA, discusses his journey into gastrointestinal oncology and the evolution of care for patients with colorectal and rectal cancers. From the complexities of multidisciplinary coordination to the promise of early-phase clinical trials, Cecchini reflects on how molecular profiling and next-generation systemic therapies are reshaping treatment paradigms.  Timestamps:   00:00 – Introduction   01:13 – Path to gastrointestinal oncology  03:00 – Multidisciplinary care challenges  07:20 – Early phase trial advances  11:26 – Evolving systemic therapies  14:58 – Impact of molecular profiling  20:20 – Translating trials to practice  23:38 – Advice for clinician investigators  28:21 – Future therapeutic advances  31:50 – Three wishes for gastrointestinal care 

In this first deep dive, Glenda Gray unpacks what antimicrobial resistance means for clinicians beyond infectious diseases, and why it is already a leading cause of death globally. She explores the disproportionate burden in low- and middle-income countries, the devastating impact on neonates and infants, and the critical role of diagnostics, vaccines, and infection prevention. Timestamps: 00:00 – Introduction 00:45 – What is AMR? 01:32 – Burden on LMICs  02:57 – Impact on infants 04:05 – Diagnostic gaps 05:10 – Comprehensive strategies

Glenda Gray joins the EMJ Podcast for a quickfire discussion on antimicrobial resistance and child health. From antibiotic misconceptions to equitable access and stewardship, she shares sharp insights into why AMR is a defining global health challenge for children today.

Description: The final deep dive episode looks ahead: stem cells, tissue transplantation, fertility preservation in cancer care, and the policy challenges limiting access to advanced male infertility treatment. A future-facing discussion on cures and equity. Timestamps: 00:00 – Introduction 01:02 – Stem cells 04:08 – Fertility preservation 05:04 – Access and cost 07:04 – Pricing variability 08:20 – What's next?

Description: In this second deep dive, Schlegel explains how microTESE transformed sperm retrieval. Learn how microsurgical precision improves outcomes, preserves testicular tissue, reduces pain, and why multidisciplinary collaboration drives high pregnancy rates. Timestamps:00:00 – Introduction 01:06 – Why the microscope? 03:09 – MicroTESE advantages 04:11 – Success rates 06:29 – Postoperative care 08:04 – Multidisciplinary approaches

In this episode of Hema Now, Anna Schuh discusses the evolution of precision medicine in haematology. From her early inspiration to pursue haematology to her pioneering work in chronic lymphocytic leukaemia, she reflects on how whole genome sequencing, single-cell technologies, and circulating tumour DNA are transforming risk prediction and treatment strategies.   Timestamps:   00:00 – Introduction  02:20 – What drew Anna to haematology  03:57 – Chronic lymphocytic leukaemia  08:55 – Genomics reshaping high risk chronic lymphocytic leukaemia  12:19 – OxPLoreD and STELLAR aims  15:52 – Liquid biopsies  19:56 – Global diagnostics implementation challenges  25:57 – Integrating molecular testing clinically  29:20 – Training future precision leaders  33:51 – Next breakthroughs in precision haematology  35:35 – Three magic wishes 

Description: In this first deep dive, Peter N. Schlegel joins host Catherine Glass to unpack non-obstructive azoospermia. Explore genetic discoveries, hormonal optimisation, age-related factors, and practical strategies that maximise sperm retrieval and conception potential. Timestamps: 00:00 – Introduction 01:13 – Non-obstructive azoospermia 02:01 – Genetics of infertility 04:01 – Aromatase inhibitors 06:05 – Sperm quality 07:27 – Multiple semen samples 10:27 – Infertility globally

In this rapid-fire episode, Peter N. Schlegel answers key questions about male infertility, from what drives success in microTESE to the role of genetics, hormones, and surgical skill. A concise introduction to the science shaping modern men's reproductive care.

Bairey Merz discusses the latest directions in microvascular and endothelial research, including links to heart failure with preserved ejection fraction, integration of adverse pregnancy outcomes and autoimmune disease into models, and promising technological advances. Timestamps: 00:53 – Directions of the WISE programme 01:47 – Preserved ejection fraction 04:51 – Adverse outcomes of microvascular disease 08:42 – Technology improving outcomes

This episode examines how diagnostic tools and imaging for microvascular dysfunction are evolving, the paradox of 'clear' arteries in symptomatic women, and barriers to broader implementation in clinical practice. Timestamps: 00:45 – Angina in women 03:43 – Defining ischaemia 05:35 – Barriers to microvascular testing

In this episode of Onc Now, Kevin Harrington discusses the evolving landscape of head and neck cancer treatment, from the transformative impact of immunotherapy to the promise of oncolytic viruses. He reflects on the challenges that defined a decade of limited progress, the integration of radiotherapy and systemic therapies, and the importance of translating innovative science into clinical benefit. With insights into salivary gland cancers, combination strategies, and advice for the next generation of oncologists, this episode offers a comprehensive look at one of oncology's most rapidly advancing fields.  Timestamps:  00:00 – Introduction  01:10 – Specialisation in head and neck cancers  03:39 – Biggest challenges   06:30 – Impact of radiotherapy   11:19 – Role of systemic therapy  16:13 – Immunotherapy   21:10 – Salivary gland cancers  28:34 – Viruses as anti-cancer agents  33:22 – Translating innovative science  38:00 – Pairing viruses for certain cancers  41:47 – Advice to young oncologists  44:29 – Important breakthroughs  47:21 – Three magic wishes 

Bairey Merz explores the science of microvascular dysfunction in women, the role of the WISE initiative, and how these findings have redefined diagnosis, preventive cardiology, and symptom assessment. Timestamps: 01:04 – Barbra Streisand Women's Heart Center 03:35 – WISE initiative 06:36 – Microvascular angina 11:11 – Preventative cardiology

Noel Bairey Merz answers rapid-fire questions on women's heart health, including misconceptions about angina, key insights from the WISE study, and emerging imaging technologies.

In the final episode, Vidur Mahajan looks ahead to the future of radiology. From AI-enabled education to convergence with genomics and pathology, this discussion explores how imaging and AI will reshape diagnostics over the next decade.   Timestamps:  00:00 – Introduction  00:51 – Exciting innovations  03:47 – Role of radiologists  05:59 – AI and education  08:40 – AI and genomics  10:55 – What's next? 

What does it take to deploy AI across national health systems? In Part 2, Vidur Mahajan shares lessons from large-scale rollouts at RadNet and Singapore's health network, covering interoperability, regulation, and success metrics.   Timestamps:  00:00 – Introduction  00:55 – Deploying CARPL  05:50 – Real-world stories  10:52 – Regulatory challenges  13:30 – Interoperability  16:17 – Success metrics 

In this episode of Hema Now, we take a deep dive into myeloproliferative neoplasms (MPN), with a particular focus on myelofibrosis, one of the most complex and challenging MPNs to manage. Ciro Rinaldi discusses what distinguishes myelofibrosis from other chronic MPNs, the biological drivers of disease progression, and the critical role of inflammation and the bone marrow microenvironment. The conversation also explores emerging combination therapies, translational research hurdles, and how the management of myelofibrosis may evolve over the next decade. Timestamps:   00:00 – Introduction  00:59 – Myeloproliferative neoplasms  04:00 – Myelofibrosis  09:58 – Ciro's interest in the field  13:39 – Disease drivers & progression to aggressive states  17:40 – Inflammation and the bone marrow environment  22:19 – Novel targets  27:45 – Splenomegaly and MPNs  32:19 – Translational research  36:25 – Future of myelofibrosis management  38:51 – Ciro's three magic wishes  

Vidur Mahajan joins host Catherine Glass to explore how imaging AI earns clinician trust. Learn how CARPL.ai bridges the gap between research and practice, ensures transparency, and empowers radiologists to evaluate and deploy AI safely.   Timestamps:  00:00 – Introduction  01:01 – Behind CARPL.ai  03:55 – Addressing scepticism  06:47 – Barriers in AI implementation  09:29 – Ensuring transparency  11:43 – Common challenges 

In this rapid-fire episode, Vidur Mahajan answers key questions about AI in radiology, from common misconceptions and bias to real-world performance, productivity tools, and what clinicians should be asking as AI enters daily imaging workflows.

Turning ideas into action, this episode focuses on how social health can be measured, funded, and implemented. Wijedoru discusses social prescribing, training clinicians to recognise disconnection, and simple steps individuals and organisations can take to strengthen social bonds. Timestamps:  01:18 – Measuring social health 03:45 – Training and infrastructure 06:20 – Social prescribing 09:15 – Everyday actions for connection 

How can stories heal? Wijedoru discusses how storytelling helps people feel seen and understood, why it belongs alongside data-driven medicine, and how initiatives like Behind Your Mask foster empathy and connection among healthcare professionals. Timestamps:  01:05 – Origins of Behind Your Mask 03:30 – Why storytelling works 06:10 – Storytelling in medical culture 08:00 – Tools beyond stories

Nuclear medicine has undergone extraordinary transformation over the past decades, and it continues to redefine how cancer is diagnosed and treated. In this episode, Ken Herrmann reflects on his journey into nuclear medicine, the rapid evolution from PET to PET-CT, and the rise of theranostics. He discusses the balance between innovation and evidence, the growing role of multidisciplinary cancer care, and what lies ahead for the field, including the potential impact of AI. This is a forward-looking conversation for clinicians and researchers at every stage of their career.  Timestamps:   00:00 – Introduction  01:07 – His journey into nuclear medicine  02:45 – Impact of nuclear medicine  03:49 – The evolution of his research  05:22 – Theranostics  06:35 – What is the next breakthrough?  08:20 – Balancing innovation with evidence-based practice   09:45 – Multidisciplinary cancer care  11:30 – Biggest challenges in nuclear medicine  13:42 – Future of nuclear medicine  14:58 – Advice to early-career clinicians  16:00 – The potential of AI  17:57 – Three magic wishes for healthcare 

In this episode, Wijedoru explains what social health really means and why it has been neglected for so long. Drawing on WHO frameworks and global experience, he explores how poor social health affects patients, communities, and healthcare systems, and why prevention must start with connection.Timestamps:01:10 – Background03:27 – Storytelling05:25 – Social health10:04 – WHO commission

Lalith Wijedoru answers rapid-fire questions on healthcare culture, loneliness, and emotional wellbeing. From lessons learned in low-resource settings to bold ideas for improving connection in hospitals, this episode introduces social health as a vital but under-recognised pillar of health.

In this final episode, Vallier explores the next steps for liver regeneration research, including stimulating liver regeneration with small molecules and lifestyle factors. He describes AI as a tool that should not be used in the wrong way, before wrapping up the discussion with his predictions for the next 5 years and the introduction of induced pluripotent stem cell clinical trials. Timestamps:00:55 – Research beyond organoids 02:01 – Lifestyle factors 03:47 – Research funding 04:13 – AI in biotechnology 05:13 – Future of regenerative medicine 07:04 – Vision for stem cell therapies

In the second episode of the series, Vallier dives into clinical translation of research to different forms of liver disease, exploring how organoids may serve as an alternative to liver transplantation, and how immune compatibility differs between the two. Timestamps:00:59 – Organoids versus transplantation 02:52 – Organoid immune compatibility 04:58 – Chronic liver diseases 06:15 – Clinical application

 In this episode of Hema Now, Catherine Glass sits down with senior leaders from the European Association for Haemophilia and Allied Disorders (EAHAD) to go behind the scenes of the EAHAD 2026 Congress. The discussion explores the vision shaping the meeting, how the scientific programme is developed, and the key advances and challenges influencing haemophilia care across Europe, offering valuable insight for clinicians and researchers alike.  Timestamps:   00:00 – Introduction  01:41 – Vision of the EAHAD 2026 Congress  03:09 – Overview of the programme  06:46 – Behind the scenes of planning a congress  09:38 – New sessions to look out for  11:03 – Their programme highlights  13:38 – How the programme is curated  15:21 – Current landscape of haemophilia care in Europe  18:09 – Major advances in the field  20:25 – Unmet needs for patients  23:31 – Real-world data and registries  25:58 – Advice to young clinicians  27:28 – Hopes for the future of haemophilia care  30:21 – Their wishes for healthcare 

In the final podcast of this three-part series, we hear expert insights into evolving guidelines, practical tools, and multidisciplinary collaboration for the optimal diagnosis and management of RCC. Explore how healthcare professionals navigate RCC in daily practice, including the latest guidelines to the streamlining of referral pathways and evaluating treatment response.

In this first deep dive, Vallier discusses the current state of liver regeneration research. He explores how pluripotent stem cells can generate hepatocytes and biliary cells, and describes how organoids integrate into tissues whilst providing new insights into liver disease. Timestamps: 00:53 – Liver regeneration at present 03:37 – Pluripotent stem cells 05:18 – Scaling clinical use of organoids 06:42 – Application to non-alcoholic fatty liver disease 09:22 – Ethical considerations

Ludovic Vallier joins the EMJ Podcast to answer rapid-fire questions about how regenerative technologies can be harnessed to tackle metabolic liver disease. From the biggest breakthroughs in regenerative hepatology to clinical misconceptions about stem cells, explore how this field of research is changing the liver disease landscape.

In the final episode, Gerber discusses how discoveries move from laboratory research into real-world patient care. Drawing on his experience in clinical trials, entrepreneurship, and national transplant policy, he shares insights into the future of transplantation and regenerative surgery.  Timestamps:  Pullquote and timestamps:  00:56 – Clinical trials  02:42 – Entrepreneurship in life sciences  04:13 – Academic institution support  06:28 – Improving organ allocation  08:02 – Future of transplant surgery 

In this second deep dive, Gerber discusses his appointment as Chair of Surgery at the University of Cincinnati, Ohio, USA, and his vision for advancing a century-long legacy of excellence. He reflects on how military and academic leadership shaped his approach to mentorship and accountability, explores the future of equity in surgical training, and offers advice to aspiring academic leaders.  Timestamps:  01:00 – Role as Chair of Surgery  02:55 – Building legacy  04:50 – Military experience  07:13 – Makeup of surgery trainees  09:09 – Early career advice 

In this episode, Robin Jones explores the complexities of sarcoma care, reflecting on his career journey, the challenges of diagnosis, and the evolving treatment landscape. The discussion spans unmet needs, promising research, and what the next decade may hold for patients with both localised and metastatic sarcomas, drawing on experience from clinical practice and trials across the UK and USA.  Timestamps:  00:00 – Introduction   00:57 – Robin's career journey  01:43 – Why sarcoma?  03:05 – Different types of sarcomas  05:09 – Diagnosis and treatment decision-making   07:19 – Challenges in recognising sarcoma  10:34 – Evolution of care for patients  13:10 – Promising therapies and research  15:25 – Working across the UK and USA  16:32 – Current unmet needs for patients  18:42 – The future of sarcoma care  21:34 – Robin's magic wishes for healthcare  

In this first deep dive, Gerber explores how regenerative medicine is reshaping transplant surgery. He discusses advances in stem cell biology, tissue engineering, and ex vivo organ preservation, and examines how these technologies may expand organ viability and redefine surgical repair.  Timestamps:  01:18 – Tissue regeneration   02:19 – Evolution beyond traditional transplantation  04:04 – Ex-vivo organ preservation  05:09 – Extending organ viability  06:34 – Promising frontiers  09:04 – Bench to bedside 

David A. Gerber joins the EMJ Podcast for a rapid-fire discussion on what drives innovation in transplant surgery. From misconceptions about organ transplantation to the technologies shaping the future of regenerative medicine, this episode offers a concise overview of a rapidly evolving field.

In this final deep dive episode, Stuart Elborn turns to healthcare systems and policy. He discusses the importance of registries, data sharing, and service organisation, alongside social and funding factors that shape equitable cystic fibrosis care, ending with a global vision for cystic fibrosis management over the next decade. Timestamps: 00:00 – Introduction 01:08 – Healthcare delivery 03:33 – National registries 05:04 – New challenges 06:35 – Equitable care 08:51 – Regional initiatives 10:40 – What's next?

In this second deep dive episode, Stuart Elborn explores the future landscape of cystic fibrosis treatment beyond modulators. From mRNA and gene editing to inhaled therapies and phenotype-driven care, this episode examines how close we are to truly personalised medicine in cystic fibrosis.  Timestamps: 00:00 – Introduction 01:22 – Treatment gaps 03:13 – Extrapulmonary complications 04:14 – Novel therapies 06:04 – Delivery routes 07:33 – Personalised medicine